MedTrace Logo

R.E.C.K vs Exparel in Robotic Nephrectomy

NCT07092566 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2026-01-20

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.

Conditions

  • Renal Carcinoma
  • Nephrectomy / Methods
  • Pain Management

Interventions

DRUG

Ropivacaine HCL

123 mg, intramuscular

DRUG

Exparel

100 mL total dose - Intramuscular (IM), intraoperatively

DRUG

Epinephrine

0.25 mg, intramuscular

DRUG

Clonidine HCL

0.04 mg, intramuscular

DRUG

Ketorolac

15 mg, intramuscular

Sponsors & Collaborators

  • Atrium Health Levine Cancer Institute

    collaborator OTHER

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Roy Ornob, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-14
Primary Completion
2027-10-31
Completion
2027-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07092566 on ClinicalTrials.gov